Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 4/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3465475 | 0.83 | NNMT (0.69) | NNMTEPHX2SMN1; SMN2HCAR3 | |
| SCHEMBL11316730 | 0.82 | NNMT (0.62) | NNMTEPHX2MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL5537643 | 0.79 | NNMT (0.63) | NNMTEPHX2RAB9ASMN1; SMN2 | |
| SCHEMBL2746892 | 0.78 | NNMT (0.61) | NNMTEPHX2SMN1; SMN2HCAR3 | |
| SCHEMBL28157252 | 0.78 | NNMT (0.70) | NNMTEPHX2SMN1; SMN2HCAR3 | |
| Acetone SCHEMBL17558521 | 0.77 | NNMT (0.69) | NNMTEPHX2SMN1; SMN2HCAR3 | |
| SCHEMBL4320704 | 0.76 | NNMT (1.00) | NNMTEPHX2SMN1; SMN2HCAR3 | |
| SCHEMBL19151094 | 0.76 | NNMT (0.63) | NNMTEPHX2MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3466195 | 0.76 | NNMT (0.63) | NNMTEPHX2RAB9ASMN1; SMN2HCAR3 | |
| SCHEMBL5734042 | 0.76 | NNMT (0.58) | NNMTEPHX2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. | 2012-08-16 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1806342-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | CNR2, CNR1, HRH4 | NNMT 2607/4885EPHX2 1166/4885MAPT 2374/4885 |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | NNMT 2706/4885EPHX2 1521/4885MAPT 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.